Imunon (NASDAQ:IMNN) Stock, Quote.Headers.trade-ideas

Imunon

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

vaccine-4892059

News

IMNN

Imunon shares are trading lower by 61% during Wednesday&#39;s session. The company announced a $10 million registered direct offering.

Why Imunon (IMNN) Stock Is Down 60% Today

Wall Street bull

Earnings

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

FGEN

FVRR

MSFT

PEPG

POWL

Nasdaq Surges Over 3%; Powell Industries Shares Spike Higher

Wall Street, US stocks

NCNC

NUZE

PMEC

Dow Jumps Over 200 Points; Kraft Heinz Shares Gain After Q2 Earnings

Imunon Inc

Press Releases

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Abpro Hldgs

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Curis

GlycoMimetics

iBio

Immuron Limited - American Depositary Shares

Immuron

IN8bio

Kairos Pharma

Moleculin Biotech

MEI Pharma

Marker Therapeutics

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

BiomX

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Polyrizon

Portage Biotech

Rallybio

SAB Biotherapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Synlogic

HC Wainwright & Co.

D. Boral Capital

EF Hutton

Alliance Global Partners

Comments

Imunon

Imunon (NASDAQ:IMNN) Stock, Quote.Headers.trade-ideas

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell